Review
Oncology
Kreina Sharela Vega Cano, David Humberto Marmolejo Castaneda, Santiago Escriva-de-Romani, Cristina Saura
Summary: Therapeutic advances have significantly improved the natural history of HER2-positive metastatic breast cancer. Double anti-HER2 blockade with a taxane is currently the best option in first-line, but T-DXd has emerged as the new standard in second-line. New treatments and combinations are being developed to address resistance and progress in these patients.
Article
Oncology
Layal Al Mahmasani, Ghid Amhaz, Reine Abou Zeidane, Nathalie Chamseddine, Taha Hatab, Saad Sabbagh, Maya Charafeddine, Hazem I. Assi
Summary: Metastatic breast cancer is a diverse disease, and the optimal treatment sequence for patients with HR-positive, HER2-negative MBC remains unknown. This study aimed to investigate oncologists' preferences in the choice and sequence of treatment for these patients. The study found a higher percentage of patients receiving chemotherapy as first-line treatment compared to the reported literature.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Mariya Rozenblit, Sophia Mun, Pamela Soulos, Kerin Adelson, Lajos Pusztai, Sarah Mougalian
Summary: This study suggests that EE remains an effective treatment option after prior ET or ET + CDK4/6i use. Median TTNT of EE was longer for patients who received prior ET, whereas median OS was longer for patients who received prior ET + CDK4/6i. However, this improvement in OS was not statistically significant when indexed to the start of EE therapy suggesting that OS benefit is primarily driven by prior CDK4/6i use. EE remains an effective treatment option regardless of prior treatment option.
BREAST CANCER RESEARCH
(2021)
Article
Oncology
Mirat Shah, Suparna Wedam, Joyce Cheng, Mallorie H. Fiero, Huiming Xia, Fang Li, Jianghong Fan, Xinyuan Zhang, Jingyu Yu, Pengfei Song, Wei Chen, Tiffany K. Ricks, Xiao Hong Chen, Kirsten B. Goldberg, Yutao Gong, William F. Pierce, Shenghui Tang, Marc R. Theoret, Richard Pazdur, Laleh Amiri-Kordestani, Julia A. Beaver
Summary: Tucatinib in combination with trastuzumab and capecitabine was approved by the FDA for the treatment of advanced HER2-positive breast cancer, with demonstrated efficacy in patients with brain metastases. The approval was based on data from the HER2CLIMB trial showing significant benefit in progression-free survival and overall survival.
CLINICAL CANCER RESEARCH
(2021)
Article
Multidisciplinary Sciences
Izzet Dogan, Esra Aydin, Nijat Khanmammadov, Nail Paksoy, Pinar Saip, Adnan Aydiner
Summary: The purpose of this study was to evaluate the prognosis and predictors of complete response for HER2-positive metastatic breast cancer patients receiving long-term trastuzumab-based therapy. Binary regression analysis was used to analyze the predictors of complete response. A total of 80 patients were included in the study, with a median trastuzumab treatment duration of 62 months. A complete response was observed in 75% of patients, with a median duration of 14.8 months. Menopausal status, the number of metastatic sites, and the use of endocrine therapy with trastuzumab were found to be significant predictors of complete response. The study highlights the potential of trastuzumab-based therapy for achieving complete cure in HER2-positive metastatic breast cancer patients, but further multicenter studies are needed to confirm these findings.
SCIENTIFIC REPORTS
(2023)
Article
Endocrinology & Metabolism
Shuhui You, Chengcheng Gong, Yi Li, Yizhao Xie, Yumeng Li, Yannan Zhao, Biyun Wang
Summary: In HoR-positive MBC, patients with low and zero HER2 expression have similar clinical characteristics and respond similarly to endocrine treatment, but the chemotherapy effect is worse in the HER2-low patients. Moreover, the transformation of HER2 status from primary to metastatic lesions may have potential influence on chemotherapy outcomes.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Grazia Arpino, Juan de la Haba Rodriguez, Jean -Marc Ferrero, Sabino De Placido, Dirk Klingbiel, Valentine Revelant, Christine Wohlfarth, Raf Poppe, Mothaffar F. Rimawi
Summary: The addition of pertuzumab to trastuzumab and an aromatase inhibitor significantly improved progression-free survival in patients with previously untreated HER2-positive and hormone receptor-positive breast cancer. The treatment effect of pertuzumab may be enhanced in patients who do not require chemotherapy.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Bora Lim, David A. Potter, Mohamad A. Salkeni, Paula Silverman, Tufia C. Haddad, Frederic Forget, Ahmad Awada, Jean-Luc Canon, Michael Danso, Alain Lortholary, Hugues Bourgeois, Elizabeth Tan-Chiu, Sylvie Vincent, Brittany Bahamon, Kevin J. Galinsky, Chirag Patel, Rachel Neuwirth, E. Jane Leonard, Jennifer R. Diamond
Summary: The study evaluated the efficacy and safety of sapanisertib plus exemestane or fulvestrant in treating advanced/metastatic hormone receptor-positive breast cancer, showing certain clinical benefit for patients. The treatment demonstrated different efficacy in patients previously sensitive or resistant to exemestane.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Susanna Nguy, S. Peter Wu, Cheongeun Oh, Naamit K. Gerber
Summary: The study found that adding HER2 therapy to endocrine therapy did not significantly improve overall survival in non-metastatic ER+/HER2+ breast cancer patients who did not receive chemotherapy.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Review
Oncology
Ismail Essadi, Zineb Benbrahim, Mohamed Kaakoua, Thibaut Reverdy, Pauline Corbaux, Gilles Freyer
Summary: Since the advent of trastuzumab, the natural history of HER2-positive metastatic breast cancer has improved. Various therapies targeting HER2 have been developed, including anti-HER2 double blockade and trastuzumab-deruxtecan, which have improved overall survival. However, the benefit of these therapies in patients with brain metastases is still unclear. The introduction of tucatinib, a new tyrosine kinase inhibitor, has shown promise for the treatment of these patients. This article reviews established drugs and novel agents for HER2-positive MBC and discusses their incorporation into different treatment settings.
Review
Oncology
Moudi M. Alasmari
Summary: This article reviews the clinical implications and efficacy of margetuximab as an anti-HER2 drug in the treatment of HER2-positive metastatic breast cancer, and concludes that margetuximab is an effective treatment for this disease.
Editorial Material
Oncology
Alicia F. C. Okines, Nicholas C. Turner
Summary: HER2 amplification heterogeneity is linked to resistance to trastuzumab emtansine in the neoadjuvant setting, highlighting the significance of determining whether varying HER2-positive cancer types require distinct treatment approaches.
Review
Oncology
Veronique Debien, Evandro de Azambuja, Martine Piccart-Gebhart
Summary: Triple-positive breast tumors overexpress HER2 and are positive for HR expression. ER expression affects the response to anti-HER2 and associated systemic therapies. Optimizing dual anti-HER2 blockade is important for disease control in triple-positive tumors.
CANCER TREATMENT REVIEWS
(2023)
Review
Oncology
G. Nader-Marta, D. Martins-Branco, E. de Azambuja
Summary: HER2-positive breast cancer is a subtype of breast malignancy with aggressive behavior and high recurrence rates. The combination of trastuzumab, pertuzumab, and a taxane remains the preferred first-line therapy. Recent studies have shown that trastuzumab deruxtecan is more effective than trastuzumab emtansine as a second-line treatment. Other treatment options include T-DM1, tucatinib, trastuzumab, and capecitabine, as well as trastuzumab with different chemotherapy partners.
Review
Oncology
Joohyun Hong, Yeon Hee Park
Summary: Significant progress has been made in the treatment of HER2-positive breast cancer, especially with the development of targeted therapies. Different treatment approaches are applied based on the risk level and presence of residual disease, including adjuvant trastuzumab, pertuzumab, paclitaxel, and other drugs. Ongoing trials are exploring the combination of novel agents and de-escalation of treatment in the neoadjuvant setting, aiming to achieve better outcomes.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)